Science news

Leading Innovators in Medication Adherence: Profiles of Top Companies Driving Healthcare Transformation

DUBLIN, Oct. 19, 2023 /PRNewswire/ -- The "Medication Adherence Devices - A Global and Regional Analysis: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...

HealthPRO Canada Signs Two Inaugural Agreements through Innovation Accelerator Program

OAKVILLE, ON, Oct. 19, 2023 /CNW/ - HealthPRO Canada is pleased to announce signing its first two agreements with innovative suppliers through its new...

APCI to Feds: Stop Further Healthcare Vertical Integration in Optum-Amedisys Deal

BESSEMER, Ala., Oct. 19, 2023 /PRNewswire/ -- The federal government should prevent UnitedHealth Group's Optum division from acquiring Amedisys home health, according to a...

Changing the Trajectory of Breast Cancer in Europe: How Advanced Screening Can Make a Difference

DUBLIN, Oct. 18, 2023 /PRNewswire/ -- In a world where breast cancer awareness is more critical than ever, a groundbreaking research report, titled "Europe...

Dr. Huda Zoghbi Reveals New Research Into the Mechanisms Driving Rett Syndrome at the 2023 World Congress of Neurology

MONTREAL, Oct. 18, 2023 /CNW/ -- Huda Zoghbi, MD, professor of molecular and human genetics, Baylor College of Medicine, has made a groundbreaking discovery...

Capacity-Building Alliance of Sustainable Investment (CASI) announced in Beijing

BEIJING, Oct. 18, 2023 /PRNewswire/ -- China's leading green finance think tank, the Beijing-based Institute of Finance and Sustainability (IFS), unveiled a global initiative...

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive1ZILBRYSQ...

Latest articles